{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T18:13:14Z","timestamp":1770747194914,"version":"3.49.0"},"reference-count":16,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"11","license":[{"start":{"date-parts":[[2022,3,18]],"date-time":"2022-03-18T00:00:00Z","timestamp":1647561600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/cc-by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Levosimendan and dobutamine are extensively used to treat sepsis-induced cardiomyopathy. Previous studies on whether levosimendan is superior to dobutamine are still controversial. We performed a protocol for systematic review and metaanalysis to compare the efficacy and safety of levosimendan versus dobutamine for the treatment of sepsis-induced cardiomyopathy.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>This protocol follows the Preferred Reporting Items for Systematic Reviews and Meta-Analyses protocol statement. We will search the following databases: PubMed, Embase, Web of Science, Cochrane Library, China National Knowledge Infrastructure, Wanfang Database, Weipu Journal Database, and Chinese Biomedical Literature Database. The search time will be set from database establishment to February 2022. After literature screening, 2 reviewers will extract data from the respects of general information, methodology, and results. Risk of bias is assessed using the Cochrane Risk of Bias Tool for randomized controlled trials. We will apply RevMan 5.4 software for statistical analysis.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>The results will be submitted to a peer-reviewed journal once completed.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>Septic patients with myocardial dysfunction may partly benefit from levosimendan than dobutamine, mainly embodied in cardiac function improvement.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000029092","type":"journal-article","created":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T13:10:37Z","timestamp":1648732237000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":4,"title":["Comparison of dobutamine and levosimendan for treatment of sepsis-induced cardiac dysfunction"],"prefix":"10.1097","volume":"101","author":[{"given":"Jun","family":"Guo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xianhuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanan","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5445-7650","authenticated-orcid":false,"given":"Qiong","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2022,3,18]]},"reference":[{"key":"R1-47-20250504","first-page":"121","article-title":"Cardiovascular dysfunction in sepsis: from basic mechanisms to clinical management.","volume":"11","author":"Liaudet","year":"2013","journal-title":"Curr Vasc Pharmacol"},{"key":"R2-47-20250504","doi-asserted-by":"crossref","first-page":"117821","DOI":"10.1016\/j.lfs.2020.117821","article-title":"Molecular mechanisms by which iNOS uncoupling can induce cardiovascular dysfunction during sepsis: role of posttranslational modifications (PTMs).","volume":"255","author":"Sharawy","year":"2020","journal-title":"Life Sci"},{"key":"R3-47-20250504","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1097\/CRD.0000000000000301","article-title":"Myocardial depression in sepsis: beneficial adaptation or sequelae that requires treatment?","volume":"28","author":"Rumery","year":"2020","journal-title":"Cardiol Rev"},{"key":"R4-47-20250504","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.jcrc.2014.03.028","article-title":"Myocardial depression in sepsis: from pathogenesis to clinical manifestations and treatment.","volume":"29","author":"Antonucci","year":"2014","journal-title":"J Crit Care"},{"key":"R5-47-20250504","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1097\/CCM.0b013e31827e83af","article-title":"Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012.","volume":"41","author":"Dellinger","year":"2013","journal-title":"Crit Care Med"},{"key":"R6-47-20250504","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1007\/s00134-013-2982-0","article-title":"Effects of dobutamine on systemic, regional and microcirculatory perfusion parameters in septic shock: a randomized, placebo-controlled, double-blind, crossover study.","volume":"39","author":"Hernandez","year":"2013","journal-title":"Intensive Care Med"},{"key":"R7-47-20250504","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1111\/aas.12056","article-title":"Association between inotrope treatment and 90-day mortality in patients with septic shock.","volume":"57","author":"Wilkman","year":"2013","journal-title":"Acta Anaesthesiol Scand"},{"key":"R8-47-20250504","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1177\/0300060519837103","article-title":"Levosimendan as a new force in the treatment of sepsis-induced cardiomyopathy: mechanism and clinical application.","volume":"47","author":"Yang","year":"2019","journal-title":"J Int Med Res"},{"key":"R9-47-20250504","doi-asserted-by":"crossref","first-page":"e19338","DOI":"10.1136\/bmjopen-2017-019338","article-title":"Effect of levosimendan on mortality in severe sepsis and septic shock: a meta-analysis of randomised trials.","volume":"8","author":"Chang","year":"2018","journal-title":"BMJ Open"},{"key":"R10-47-20250504","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1056\/NEJMoa1609409","article-title":"Levosimendan for the prevention of acute organ dysfunction in sepsis.","volume":"375","author":"Gordon","year":"2016","journal-title":"N Engl J Med"},{"key":"R11-47-20250504","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/2046-4053-4-1","article-title":"Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement.","volume":"4","author":"Moher","year":"2015","journal-title":"Syst Rev"},{"key":"R12-47-20250504","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomized trials.","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"R13-47-20250504","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1007\/s00134-017-4683-6","article-title":"Surviving sepsis campaign: international guidelines for management of sepsis and septic shock: 2016.","volume":"43","author":"Rhodes","year":"2017","journal-title":"Intensive Care Med"},{"key":"R14-47-20250504","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1097\/SHK.0000000000001718","article-title":"The long-term effect of dobutamine on intrinsic myocardial function and myocardial injury in septic rats with myocardial dysfunction.","volume":"56","author":"Tang","year":"2021","journal-title":"Shock"},{"key":"R15-47-20250504","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.medin.2017.08.009","article-title":"Levosimendan in patients with cardiogenic shock complicating myocardial infarction: a meta-analysis.","volume":"42","author":"Fang","year":"2018","journal-title":"Med Intensiva (Engl Ed)"},{"key":"R16-47-20250504","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S0022-3565(24)36997-6","article-title":"The novel calcium sensitizer levosimendan activates the ATP-sensitive K+ channel in rat ventricular cells.","volume":"283","author":"Yokoshiki","year":"1997","journal-title":"J Pharmacol Exp Ther"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000029092","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T04:23:33Z","timestamp":1746332613000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000029092"}},"subtitle":["A protocol for systematic review and meta-analysis"],"short-title":[],"issued":{"date-parts":[[2022,3,18]]},"references-count":16,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000029092","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,18]]},"assertion":[{"value":"2022-02-06","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-02-26","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}